Karyopharm Therapeutics (NASDAQ:KPTI) Rating Lowered to Hold at StockNews.com

StockNews.com lowered shares of Karyopharm Therapeutics (NASDAQ:KPTI) from a buy rating to a hold rating in a research report sent to investors on Friday.

A number of other brokerages have also commented on KPTI. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Karyopharm Therapeutics in a research report on Friday, November 1st. Robert W. Baird decreased their price objective on Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. Piper Sandler increased their target price on Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $3.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

Karyopharm Therapeutics Stock Performance

Karyopharm Therapeutics stock opened at $0.84 on Friday. The stock has a market capitalization of $105.27 million, a price-to-earnings ratio of -0.74 and a beta of 0.16. Karyopharm Therapeutics has a 52-week low of $0.62 and a 52-week high of $1.95. The stock’s 50 day moving average price is $0.83 and its two-hundred day moving average price is $0.89.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Tuesday, November 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.01. The company had revenue of $38.78 million for the quarter, compared to the consensus estimate of $37.86 million. During the same period in the prior year, the company earned ($0.30) earnings per share. On average, equities research analysts forecast that Karyopharm Therapeutics will post -0.94 EPS for the current year.

Institutional Trading of Karyopharm Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Point72 DIFC Ltd bought a new stake in Karyopharm Therapeutics during the second quarter worth $31,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Karyopharm Therapeutics during the 2nd quarter worth $143,000. Acadian Asset Management LLC purchased a new position in Karyopharm Therapeutics during the 2nd quarter worth $167,000. Exchange Traded Concepts LLC raised its holdings in shares of Karyopharm Therapeutics by 34.9% in the third quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock valued at $182,000 after purchasing an additional 56,613 shares during the last quarter. Finally, FMR LLC lifted its position in shares of Karyopharm Therapeutics by 26.1% during the third quarter. FMR LLC now owns 369,723 shares of the company’s stock valued at $307,000 after purchasing an additional 76,510 shares in the last quarter. 66.44% of the stock is owned by hedge funds and other institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).